Impact of transferable β-lactamases and intrinsic AmpC amino acid substitutions on the activity of cefiderocol against wild-type and iron uptake-deficient mutants of Pseudomonas aeruginosa
Authors:
- Lucía González-PintoLGLucía González-Pinto
- Tania Blanco-MartínTBTania Blanco-Martín
- Isaac Alonso-GarcíaIAIsaac Alonso-García
- Salud Rodríguez-PallaresSRSalud Rodríguez-Pallares
- Michelle Outeda-GarcíaMOMichelle Outeda-García
- María Antonia Gomis-FontMGMaría Antonia Gomis-Font
- Pablo Arturo Fraile-RibotPFPablo Arturo Fraile-Ribot
- Juan Carlos Vázquez-UchaJuan Carlos Vázquez-Ucha
- Concepción González-BelloConcepción González-Bello
- Alejandro BeceiroABAlejandro Beceiro
- Germán BouGBGermán Bou
- 17 September 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 79 (11) , 3023-3028
Abstract
We aimed to analyse the interplay between impaired iron uptake and β-lactamases on cefiderocol resistance in Pseudomonas aeruginosa. Thirty-one transferable β-lactamases and 16 intrinsic P. aeruginosa AmpC (PDC) variants were cloned and expressed in wild-type (PAO1) and iron uptake-deficient (PAO ΔpiuC) P. aeruginosa backgrounds. MICs of cefiderocol and antipseudomonal β-lactams were determined by reference broth microdilution. Relative to PAO1, deletion of piuC caused a specific 16-fold decrease in cefiderocol activity but negligible effects on the activity of other β-lactams. Among transferable β-lactamases, SHV-12, KPC Ω-loop mutants, NDMs and OXA-15 showed cefiderocol MIC values above the clinical breakpoint (2 mg/L) when expressed in PAO1. When expressed in PAO ΔpiuC, these and the transformants harbouring PER-1, VEB-1, KPC-2, KPC-3, VIM-1, CMY-2, OXA-2 and OXA-14 showed increased MIC values from 16 to >256 mg/L. The PDC variants carrying the Ω-loop changes ΔP215-G222 (PDC-577), E219K (PDC-221 and PDC-558) and the H10 helix change L293P (PDC-219) had the greatest impact on cefiderocol resistance, with MICs of 2–4 mg/L in PAO1 and of up to 32–64 mg/L in PAO ΔpiuC. Widespread enzymes such as GES, CTX-M-9, CTX-M-15, VIM-2-like enzymes, IMPs, DHA-1, FOX-4, OXA-10, OXA-48 and the other PDC variants tested had weaker effects on cefiderocol resistance. We add evidence about the effect of the interplay between iron uptake and β-lactamases on the acquisition of cefiderocol resistance in P. aeruginosa. These findings may help to anticipate the emergence of resistance and optimize the use of cefiderocol against P. aeruginosa infections.Keywords
Funding Information
- Instituto de Salud Carlos III (PI23/00851, PI22/01212, PI21/00704, PI21/00017, PI20/01212)
- European Union
- CIBER de Enfermedades Infecciosas (CB21/13/00055, CB21/13/00099)
- General Subdirection of Assessment and Promotion of the Research
- European Regional Development Fund
- Axencia Galega de Innovación
- CONSELLERÍA DE INNOVACIÓN
- Consellería de Economía, Emprego e Industria (IN607D 2021/12, IN607A 2016/22)
- Spanish State Agency of Research
- Xunta de Galicia (ED431C 2021/29)
- Centro Singular de Investigación de Galicia (ED431G 2019/03)
- PFIS
- Rio Hortega program
- Juan Rodés program
- Rio Hortega program
- ISCII (CM23/00104, IN606A 2023/023)
- PFIS
- Juan Rodés program
This publication has 15 references indexed in Scilit:
- Pseudomonas aeruginosa antibiotic susceptibility profiles, genomic epidemiology and resistance mechanisms: a nation-wide five-year time lapse analysisThe Lancet Regional Health - Europe, 2023
- In vitro dynamics and mechanisms of cefiderocol resistance development in wild-type, mutator and XDR Pseudomonas aeruginosaJournal of Antimicrobial Chemotherapy, 2023
- Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosaJournal of Antimicrobial Chemotherapy, 2022
- Impact of Acquired Broad-Spectrum β-Lactamases on Susceptibility to Cefiderocol and Newly Developed β-Lactam/β-Lactamase Inhibitor Combinations in Escherichia coli and Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2022
- In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infectionClinical Microbiology and Infection, 2022
- Molecular mechanisms driving thein vivodevelopment of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDRPseudomonas aeruginosainfectionsJournal of Antimicrobial Chemotherapy, 2020
- Molecular and biochemical insights into the in vivo evolution of AmpC-mediated resistance to ceftolozane/tazobactam during treatment of an MDR Pseudomonas aeruginosa infectionJournal of Antimicrobial Chemotherapy, 2020
- Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore CephalosporinClinical Infectious Diseases, 2019
- Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal CephalosporinsAntimicrobial Agents and Chemotherapy, 2015
- Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii : Mechanisms and epidemiologyInternational Journal of Antimicrobial Agents, 2015